1.58

1.94% 0.03

After Hours: 1.57 -0.01 -0.63%

Pacific Biosciences Of California Inc (PACB)

Overview News Price History Option Chain Financials Why PACB Down? Discussions Forecast

Pacific Biosciences Of California Inc stock is traded at $1.58, with a volume of 5.79M. It is up +1.94% in the last 24 hours and up +17.91% over the past month. Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Previous Close:

$1.55

Open:

$1.55

24h Volume:

5.79M

Relative Volume:

0.94

Market Cap:

$490.57M

Revenue:

$160.01M

Net Income/Loss:

$-546.38M

P/E Ratio:

-0.861

EPS:

-1.835

Net Cash Flow:

$-118.92M

1W Performance:

+0.00%

1M Performance:

+17.91%

6M Performance:

-17.49%

1Y Performance:

+42.34%

1-Day Range:

$1.50

$1.58

1-Week Range:

$1.4201

$1.62

52-Week Range:

$0.8511

$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Name

Pacific Biosciences Of California Inc

Sector

Healthcare (1106)

Industry

Medical Devices (142)

Phone

650-521-8000

Address

1305 O'BRIEN DRIVE, MENLO PARK, CA

Employee

485

Twitter

@pacbio

Next Earnings Date

2026-05-07

Latest SEC Filings

PACB's Discussions on Twitter

Compare PACB vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PACB Pacific Biosciences Of California Inc	1.58	481.26M	160.01M	-546.38M	-118.92M	-1.835
ABT Abbott Laboratories	87.17	152.48B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	295.25	111.40B	25.27B	3.34B	4.57B	8.6358
MDT Medtronic Plc	77.79	100.53B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	55.98	84.50B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	82.91	48.04B	6.30B	1.07B	1.34B	1.8406

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-06-26	Downgrade	Barclays	Equal Weight → Underweight
Nov-11-24	Downgrade	UBS	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Buy
Apr-22-24	Downgrade	JP Morgan	Overweight → Neutral
Apr-18-24	Downgrade	Goldman	Buy → Neutral
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-14-23	Initiated	Stephens	Overweight
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-17-23	Upgrade	UBS	Neutral → Buy
Oct-31-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Jul-05-23	Resumed	JP Morgan	Overweight
Jun-30-23	Initiated	Goldman	Buy
May-10-23	Initiated	Barclays	Equal Weight
Mar-31-23	Upgrade	TD Cowen	Market Perform → Outperform
Feb-02-23	Initiated	UBS	Neutral
Jan-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-21-22	Resumed	Cantor Fitzgerald	Overweight
Jan-06-22	Resumed	Piper Sandler	Neutral
Oct-15-21	Resumed	Cowen	Market Perform
Sep-27-21	Initiated	Canaccord Genuity	Buy
Feb-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Nov-03-20	Downgrade	Piper Sandler	Overweight → Neutral
Oct-02-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight
Mar-09-20	Resumed	Cantor Fitzgerald	Overweight
Oct-15-19	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-02-19	Downgrade	Stephens	Overweight → Equal-Weight
Oct-19-18	Initiated	Cowen	Outperform
Nov-03-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-28-17	Downgrade	CL King	Buy → Neutral
Nov-03-16	Reiterated	Cantor Fitzgerald	Buy
Jun-27-16	Initiated	CL King	Buy
Apr-15-16	Initiated	First Analysis Sec	Overweight
Feb-04-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jan-04-16	Reiterated	Cantor Fitzgerald	Buy
Oct-23-15	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-27-15	Initiated	Cantor Fitzgerald	Buy
Feb-04-15	Reiterated	Maxim Group	Buy
Sep-26-13	Reiterated	Maxim Group	Buy
Jan-14-13	Reiterated	Maxim Group	Buy

View All

Pacific Biosciences Of California Inc Stock (PACB) Latest News

08:25 AM

Pacific Biosciences of California pushes whole genome sequencing to transform newborn care - Traders Union

08:25 AM

11:50 AM

PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now? - Yahoo Finance

11:50 AM

03:36 AM

NGS-based RNA-seq Market Size Accelerating at 14.8% CAGR | By Key - openPR.com

03:36 AM

May 04, 2026

AI powers deep genomics gains as Pacific Biosciences of California improves sequencing accuracy and reduces costs - Traders Union

May 04, 2026

May 02, 2026

MSN Money - MSN

May 02, 2026

Apr 30, 2026

Pacific Biosciences of California presents new AAV workflow to reduce partial snapback genomes - Traders Union

Apr 30, 2026

Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill

Apr 30, 2026

Apr 29, 2026

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Apr 29, 2026

PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN

Apr 29, 2026

Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight - GlobeNewswire Inc.

Apr 29, 2026

Apr 28, 2026

PacBio and DNAstack collaborate on global HiFi genome network hub - MSN

Apr 28, 2026

Apr 27, 2026

Sequencing performance advances drive Pacific Biosciences of California to revamp SMRT Cell 101 resource - Traders Union

Apr 27, 2026

Apr 26, 2026

Here's why you should add PacBio stock to your portfolio now - MSN

Apr 26, 2026

Apr 25, 2026

Pacific Biosciences of California (PACB) laps the stock market: Here's why - MSN

Apr 25, 2026

Apr 24, 2026

Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Apr 24, 2026